Since UM and MM are quite uncommon, the efficacy of anti-CTLA-4 and anti-PD-1 mAbs has not been specifically evaluated in large series of patients with metastatic MM and UM [16]. This evidence concerns the gene CTLA4 and Miyoshi myopathy.